The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Open accessAbstract
BACKGROUND: OVARIAN CARCINOMAS CONSIST OF AT LEAST FIVE DISTINCT DISEASES: high-grade serous, low-grade serous, clear cell, endometrioid, and mucinous. Biomarker and molecular characterization may represent a more biologically relevant basis for grouping and treating this family of tumors, rather than site of origin. Molecular characteristics have become the new standard for clinical pathology, however development of tailored type-specific therapies is hampered by a failure of basic research to recognize that model systems used to study these diseases must also be stratified. Unrelated model systems do offer value for study of biochemical processes but specific cellular context needs to be applied to assess relevant therapeutic strategies. METHODS: We have focused on the identification of clear cell carcinoma cell line models. A panel of 32 "ovarian cancer" cell lines has been classified into histotypes using a combination of mutation profiles, IHC mutation-surrogates, and a validated immunohistochemical model. All cell lines were identity verified using STR analysis. RESULTS: Many described ovarian clear cell lines have characteristic mutations (including ARID1A and PIK3CA) and an overall molecular/immuno-profile typical of primary tumors. Mutations in TP53 were present in the majority of high-grade serous cell lines. Advanced genomic analysis of bona-fide clear cell carcinoma cell lines also support copy number changes in typical biomarkers such at MET and HNF1B and a lack of any recurrent expressed re-arrangements. CONCLUSIONS: As with primary ovarian tumors, mutation status of cancer genes like ARID1A and TP53 and a general immuno-profile serve well for establishing histotype of ovarian cancer cell We describe specific biomarkers and molecular features to re-classify generic "ovarian carcinoma" cell lines into type specific categories. Our data supports the use of prototype clear cell lines, such as TOV21G and JHOC-5, and questions the use of SKOV3 and A2780 as models of high-grade serous carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 2×
“As some of the cell lines we tested are also part of a larger Cancer Cell Line Encyclopedia (CCLE) repository data set [38], we cross-validated our mutation testing with this database as well as the COSMIC database [39].”
BackgroundMethodThe Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I.-M. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,846
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712 · cited 7×
“Further, loss of ARID1A expression, demonstrated by IHC, showed good concordance with presence of known truncating mutations, as noted for primary tumor specimens [16].”
BackgroundMethodSelf-citationNovel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Kurman, R. J., & Shih, I.-M. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.03.003 · Cited by 1,073
Research works printed but not linked: 8
- JW Carlson, 2010, Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications, Int J Gynecol Pathol, 29, 310, 10.1097/PGP.0b013e3181c713a8 · doi:10.1097/pgp.0b013e3181c713a8
- AR Laury, 2011, Fallopian tube correlates of ovarian serous borderline tumors, Am J Surg Pathol, 35, 1759, 10.1097/PAS.0b013e318233b0f7 · doi:10.1097/pas.0b013e318233b0f7
- Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, <etal>et al</etal>.. (2011) Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 205: 480 e481–488. · doi:10.1016/j.ajog.2011.06.049
- Kommoss S, Gilks CB, Kommoss F, Anglesio MS, Chow C, <etal>et al</etal>.. (2013) Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. Histopathology (accepted June 2, 2013). · DOI
- M Kobel, 2011, Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites, Int J Gynecol Pathol, 30, 366, 10.1097/PGP.0b013e31820d20ba · DOI
- Farley JH, Brady WE, Birrer MJ, Lankes H, Coleman R, <etal>et al</etal>.. (2012) A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum. AACR Annual Meeting 2012, Chicogo, IL, USA. · doi:10.1158/1538-7445.am2012-ct-05
- E Hernandez, 1984, Interobserver variability in the interpretation of epithelial ovarian cancer, Gynecol Oncol, 17, 117, 10.1016/0090-8258(84)90065-9 · doi:10.1016/0090-8258(84)90065-9
- A Sakamoto, 1994, Observer disagreement in histological classification of ovarian tumors in Japan, Gynecol Oncol, 54, 54, 10.1006/gyno.1994.1165 · doi:10.1006/gyno.1994.1165
Cited by
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
“Among 23 EOC lines examined, IRF7 was hypermethylated in only one, A2780 (Li et al., 2014) (Figure S3A), potentially not a classic high-grade EOC (Anglesio et al., 2013; Cell 162, 974–986, August 27, 2015 ª2015 Elsevier Inc. 975 Figure 2.”
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Self-citationLabel-free detection and molecular profiling of exosomes with a nano-plasmonic sensor
Im, H., Shao, H., Park, Y. I., Peterson, V. M., Castro, C. M., Weissleder, R., & Lee, H. (2014) · Nature Biotechnology · doi:10.1038/nbt.2886 · Cited by 1,321
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Bitler, B. G., Aird, K. M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A. V., Schultz, D. C., Liu, Q., Shih, I.-M., Conejo-Garcia, J. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3799 · Cited by 678
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403
“Comparison of our results with the two earlier studies [31,57] shows similar prediction for HGS and some discrepancies for the non-serous cell lines.”
MethodResultMukherjee, A., Chiang, C.-Y., Daifotis, H. A., Nieman, K. M., Fahrmann, J. F., Lastra, R. R., Romero, I. L., Fiehn, O., & Lengyel, E. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1999 · Cited by 304
Choosing the right cell line for renal cell cancer research
Brodaczewska, K. K., Szczylik, C., Fiedorowicz, M., Porta, C., & Czarnecka, A. M. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0565-8 · Cited by 267
Characterization of Ovarian Cancer Cell Lines as In Vivo Models for Preclinical Studies
Hernandez, L., Kim, M. K., Lyle, L. T., Bunch, K. P., House, C. D., Ning, F., Noonan, A. M., & Annunziata, C. M. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.05.028 · Cited by 121
AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
Sahin, I., Zhang, S., Navaraj, A., Zhou, L., Dizon, D., Safran, H., & El-Deiry, W. S. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0292-1 · Cited by 66
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66
The Endometriotic Tumor Microenvironment in Ovarian Cancer
Wendel, J. R. H., Wang, X., & Hawkins, S. M. (2018) · Cancers · doi:10.3390/cancers10080261 · Cited by 51
Mesothelial Cells Facilitate Cancer Stem like properties in spheroids of ovarian cancer cells
Shishido, A., Mori, S., Yokoyama, Y., Hamada, Y., Minami, K., Qian, Y., Wang, J., Hirose, H., Wu, X., Kawaguchi, N., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6605 · Cited by 34
“Furthermore, the genetic expression profile of SKOV3 cells was different from that of other serous carcinoma types (23-25).”
BackgroundHeredia-Soto, V., Redondo, A., Berjón, A., Miguel-Martín, M., Díaz, E., Crespo, R., Hernández, A., Yébenes, L., Gallego, A., Feliu, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25098 · Cited by 33
Chang, C. Y.-Y., Tseng, C.-C., Lai, M.-T., Chiang, A.-J., Lo, L.-C., Chen, C.-M., Yen, M.-J., Sun, L., Yang, L., Hwang, T., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0248168 · Cited by 20
“Two ovarian cancer cell lines, ES-2 and TOV-21G which were believed to arise in endometriosis background [29], were utilized in a gene knockdown study.”
MethodDickson, K.-A., Xie, T., Evenhuis, C., Ma, Y., & Marsh, D. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168506 · Cited by 11
Metadata
- Authors
- Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C., Prentice, L. M., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., Shumansky, K., Shah, S. P., Kalloger, S. E., & Huntsman, D. G.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-09-04
- Volume
- 8
- Issue
- 9
- Pages
- e72162
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2025669441
- Cited by
- 253
- References
- 85
- FWCI
- 23.70
- Type
- journal article
- Language
- en
- Update notices
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.